{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T01:10:00Z","timestamp":1784855400219,"version":"3.55.0"},"reference-count":43,"publisher":"Akademiai Kiado Zrt.","issue":"29","content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2022,7,17]]},"abstract":"<jats:p>A gl\u00fckagonszer\u0171 peptid-1 receptor\u00e1nak agonist\u00e1i napjainkban a 2-es t\u00edpus\u00fa\n                    diabetes v\u00e9rcukorcs\u00f6kkent\u0151 kezel\u00e9s\u00e9nek meghat\u00e1roz\u00f3 k\u00e9sz\u00edtm\u00e9nyei. M\u00e1ra\n                    kikrist\u00e1lyosodtak ad\u00e1suk lehet\u0151s\u00e9gei: a fel- (step-up) \u00e9s a le\u00e9p\u00edt\u0151 (step-down),\n                    vagy elterjedt \u00faj kelet\u0171 kifejez\u00e9ssel, a deeszkal\u00e1ci\u00f3s antidiabetikumkezel\u00e9sben\n                    val\u00f3 r\u00e9szv\u00e9tel\u00fck, a m\u00e1r hozz\u00e1f\u00e9rhet\u0151 oralis v\u00e1ltozatnak a parenteralis\n                    k\u00e9sz\u00edtm\u00e9nyform\u00e1val szemben mutatkoz\u00f3 el\u0151nyei \u00e9s potenci\u00e1lis h\u00e1tr\u00e1nyai, valamint\n                    a b\u00e1zisinzulinnal kombin\u00e1lt, fix \u00f6sszet\u00e9tel\u0171 v\u00e1ltozataik lehets\u00e9ges\n                    differenci\u00e1l\u00e1si lehet\u0151s\u00e9gei. E k\u00e9rd\u00e9seket tekinti \u00e1t munk\u00e1nk, de kit\u00e9r a\n                    gy\u00f3gyszercsoporttal kapcsolatos \u00fajabb kutat\u00e1sokra, a fejleszt\u00e9s alatt \u00e1ll\u00f3 \u00faj,\n                    r\u00e9szben kombin\u00e1ci\u00f3s k\u00e9sz\u00edtm\u00e9nyekre is. Felh\u00edvja a figyelmet e csoport k\u00e9pvisel\u0151i\n                    \u2013 els\u0151sorban hossz\u00fa hat\u00e1s\u00fa sz\u00e1rmaz\u00e9kai \u2212 korai alkalmaz\u00e1s\u00e1nak jelent\u0151s\u00e9g\u00e9re,\n                    cardiorenalis v\u00e9d\u0151hat\u00e1s\u00e1ra \u00e9s a m\u00e9g sz\u00e9lesebb k\u00f6r\u0171 haszn\u00e1latuk \u00e9rdek\u00e9ben\n                    sz\u00fcks\u00e9ges folyamatos orvosszakmai t\u00e1j\u00e9koztat\u00e1s, valamint betegeduk\u00e1ci\u00f3\n                    fontoss\u00e1g\u00e1ra. Orv Hetil. 2022; 163(29): 1144\u20131151.<\/jats:p>","DOI":"10.1556\/650.2022.32547","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T23:58:30Z","timestamp":1668815910000},"page":"1144-1151","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.1","source":"Crossref","is-referenced-by-count":2,"title":["GLP1-receptor-agonist\u00e1k a 2-es t\u00edpus\u00fa diabetes v\u00e9rcukorcs\u00f6kkent\u0151 kezel\u00e9s\u00e9ben"],"prefix":"10.1556","volume":"163","author":[{"given":"G\u00e1bor","family":"Winkler","sequence":"first","affiliation":[{"name":"\u00c9szak-K\u00f6z\u00e9p-budai Centrum, \u00daj Szent J\u00e1nos K\u00f3rh\u00e1z \u00e9s Szakrendel\u0151 Budapest, Di\u00f3s \u00e1rok 1\u20133., 1125 Magyarorsz\u00e1g"},{"name":"Miskolci Egyetem, Eg\u00e9szs\u00e9gtudom\u00e1nyi Kar, Elm\u00e9leti Eg\u00e9szs\u00e9gtudom\u00e1nyi Int\u00e9zet Miskolc Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/dom.13479","article-title":"Impact on HbA1c and body weight of switching from other GLP-1 receptor agonists to semaglutide: a model-based approach","volume":"21","author":"1 Overgaard","year":"2019","unstructured":"1 Overgaard RV, Lindberg S\u00d8, Thielke D, et al. Impact on HbA1c and body weight of switching from other GLP-1 receptor agonists to semaglutide: a model-based approach. Diabetes Obes Metab. 2019; 21: 43-51.","journal-title":"Diabetes Obes Metab"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s13300-020-00977-w","article-title":"Glucagon-like peptide-1 receptor agonist utilization in type 2 diabetes in Japan: a retrospective database analysis (JDDM 57)","volume":"12","author":"2 Ishigaki","year":"2021","unstructured":"2 Ishigaki Y, Strizek A, Aranishi T, et al. Glucagon-like peptide-1 receptor agonist utilization in type 2 diabetes in Japan: a retrospective database analysis (JDDM 57). Diabetes Ther. 2021; 12: 345-361.","journal-title":"Diabetes Ther"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2042018821997320","DOI":"10.1177\/2042018821997320","article-title":"GLP-1 receptor agonists: an updated review of head-to-head clinical studies","volume":"12","author":"3 Trujillo","year":"2021","unstructured":"3 Trujillo JM, Nuffer W, Smith BA. GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2021; 12: 2042018821997320.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"721135","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 receptor agonists: beyond their pancreatic effects","volume":"12","author":"4 Zhao","year":"2021","unstructured":"4 Zhao X, Wang M, Wen Z, et al. GLP-1 receptor agonists: beyond their pancreatic effects. Front Endocrinol. 2021; 12: 721135.","journal-title":"Front Endocrinol"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5 Dal Canto E, Ceriello A, Ryd\u00e9n L, et al. Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol. 2019; 26(2_Suppl): 25-32.","DOI":"10.1177\/2047487319878371"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6 Winkler G. Complementer and additive effects - pathobiochemical background of cardiorenal advantages of GLP-1 receptor agonists and SGLT-2 inhibitors. [Komplementer \u00e9s addit\u00edv hat\u00e1sok - a GLP-1 receptoragonist\u00e1k \u00e9s az SGLT-2 g\u00e1tl\u00f3k kardioren\u00e1lis el\u0151nyeinek patobiok\u00e9miai h\u00e1ttere.] Diabetol Hung. 2021; 29: 279-287. [Hungarian]","DOI":"10.24121\/dh.2021.17"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7 Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2020; 63: 221-228. \u00e9s Diabetes Care 2020; 43: 487-493 . Erratum: Diabetes Care 2020; 43: 1670.","DOI":"10.2337\/dc20-er07"},{"key":"ref7","unstructured":"8 Ministry of Human Resources health professional guidelines for the diagnosis of diabetes mellitus and the antihyperglycemic treatment and care of diabetics in adulthood. [Az Emberi Er\u0151forr\u00e1sok Miniszt\u00e9riuma eg\u00e9szs\u00e9g\u00fcgyi szakmai ir\u00e1nyelve a diabetes mellitus k\u00f3rism\u00e9z\u00e9s\u00e9r\u0151l, a cukorbetegek antihyperglykaemi\u00e1s kezel\u00e9s\u00e9r\u0151l \u00e9s gondoz\u00e1s\u00e1r\u00f3l feln\u0151ttkorban.] E\u00fc K\u00f6zl. 2020; 70(12): 1759-1857. [Hungarian]"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"212607","DOI":"10.7573\/dic.212607","article-title":"Management of type 2 diabetes: consensus of organizations","volume":"9","author":"9 Quattrocchi","year":"2020","unstructured":"9 Quattrocchi E, Goldberg T, Marzella N. Management of type 2 diabetes: consensus of organizations. Drugs in Context. 2020; 9: 212607.","journal-title":"Drugs in Context"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/j.jacc.2021.02.030","article-title":"Causes and risk factors for death in diabetes: a competing-risk analysis from the SAVOR-TIMI 53 trial","volume":"77","author":"10 Cavallari","year":"2021","unstructured":"10 Cavallari I, Bhatt DL, Steg G, et al. Causes and risk factors for death in diabetes: a competing-risk analysis from the SAVOR-TIMI 53 trial. J Am Coll Cardiol. 2021; 77: 1837-1840.","journal-title":"J Am Coll Cardiol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1111\/dom.14074","article-title":"Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: a large multinational cohort study","volume":"22","author":"11 Birkeland","year":"2020","unstructured":"11 Birkeland KI, Bodegard J, Eriksson JW, et al. Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: a large multinational cohort study. Diabetes Obes Metab. 2020; 22: 1607-1618.","journal-title":"Diabetes Obes Metab"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12 Nowakowska M, Zghebi SS, Aschcroft DM, et al. The comorbidity burden of type 2 diabetes mellitus: patterns, clusters and predictions from a large English primary care cohort. BMC Med. 2019; 17: 145. Erratum: BMC Med. 2020; 18: 22.","DOI":"10.1186\/s12916-019-1373-y"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.21037\/atm.2019.01.09","article-title":"Long-acting glucagon-like peptide-1 receptor agonists - status december 2018","volume":"7","author":"13 Holst","year":"2019","unstructured":"13 Holst JJ. Long-acting glucagon-like peptide-1 receptor agonists - status december 2018. Ann Transl Med. 2019; 7: 83.","journal-title":"Ann Transl Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s12933-021-01417-0","article-title":"Oral GLP-1 analogue: perspectives and impact on athertosclerosis in type 2 diabetic patients","volume":"20","author":"Saraiva JF","year":"2021","unstructured":"14 Saraiva JF, Franco D. Oral GLP-1 analogue: perspectives and impact on athertosclerosis in type 2 diabetic patients. Cardiovasc Diabetol. 2021; 20: 235.","journal-title":"Cardiovasc Diabetol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1111\/dom.14136","article-title":"Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison","volume":"22","author":"15 Home","year":"2020","unstructured":"15 Home PD, Aroda VR, Blonde L, et al. Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison. Diabetes Obes Metab. 2020; 22: 2170-2178.","journal-title":"Diabetes Obes Metab"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1080\/13696998.2017.1409228","article-title":"An indirect treatment comparison of the efficacy of insulin degludec\/liraglutide (IDegLira) and insulin glargine\/lixisenatide (iGlarLixi) in patients wih type 2 diabetes uncontrolled on basal insulin","volume":"21","author":"16 Evans","year":"2018","unstructured":"16 Evans M, Billings LK, H\u00e5kan-Bloch J, et al. An indirect treatment comparison of the efficacy of insulin degludec\/liraglutide (IDegLira) and insulin glargine\/lixisenatide (iGlarLixi) in patients wih type 2 diabetes uncontrolled on basal insulin. J Med Econ. 2018; 21: 340-347.","journal-title":"J Med Econ"},{"key":"ref16","unstructured":"17 Winkler G. Oral or parenteral semaglutide. Aspects of their differentiated application. [Or\u00e1lis vagy parenter\u00e1lis szemaglutid. A differenci\u00e1lt alkalmaz\u00e1s szempontjai.] H\u00e1ziov Tov\u00e1bbk Szle. 2021; 26: 262-267. [Hungarian]"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"645507","DOI":"10.3389\/fendo.2021.645507","article-title":"Clinical perspectives on the use of subcutaneous and oral formulations of semaglutide","volume":"12","author":"Gallwitz B","year":"2021","unstructured":"18 Gallwitz B, Giorgino F. Clinical perspectives on the use of subcutaneous and oral formulations of semaglutide. Front Endocrinol. 2021; 12: 645507.","journal-title":"Front Endocrinol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"100387","DOI":"10.1016\/j.xcrm.2021.100387","article-title":"Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes","volume":"2","author":"19 Overgaard","year":"2021","unstructured":"19 Overgaard RV, Hertz CL, Ingwersen SH, et al. Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes. Cell Rep Med. 2021; 2: 100387.","journal-title":"Cell Rep Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40265-019-01245-3","article-title":"Clinical considerations when initiating and titrating insulin degludec\/liraglutide (IDegLira) in people with type 2 diabetes","volume":"80","author":"20 Harris","year":"2020","unstructured":"20 Harris S, Abrahamson MJ, Ceriello A, et al. Clinical considerations when initiating and titrating insulin degludec\/liraglutide (IDegLira) in people with type 2 diabetes. Drugs 2020; 80: 147-165.","journal-title":"Drugs"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.2337\/dci20-0038","article-title":"Switching from insulin bolus treatment to GLP-1 RAs added to continued basal insulin n people with type 2 diabetes on basal-bolus insulin","volume":"43","author":"21 Bolli","year":"2020","unstructured":"21 Bolli GB, Porcellati F, Meier JJ. Switching from insulin bolus treatment to GLP-1 RAs added to continued basal insulin n people with type 2 diabetes on basal-bolus insulin. Diabetes Care 2020; 43: 2333-2335.","journal-title":"Diabetes Care"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22 Rosenstock J, Nino A, Soffer J, et al. Impact of a weekly glucagon-like peptide-1 recepor agonist, albiglutide, on glycemic control and on reducing prandial insulin use in type 2 diabetes inadequately controlled on multiple insulin therapy: a randomized trial. Diabetes Care 2020; 43: 2509-2518. Comments and responses. Diabetes Care 2021; 44: e196-e197.","DOI":"10.2337\/dci21-0004"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s40268-019-0273-0","article-title":"Timing of GLP-1 receptor agonist initiation for treatment of type 2 diabetes in the UK","volume":"19","author":"23 Boye","year":"2019","unstructured":"23 Boye KS, Stein D, Matza LS, et al. Timing of GLP-1 receptor agonist initiation for treatment of type 2 diabetes in the UK. Drugs RD 2019; 19: 213-225.","journal-title":"Drugs RD"},{"key":"ref23","unstructured":"24 Morris D. GLP-1 receptor agonists in type 2 diabetes: an underused asset? J Diabetes Nurs. 2020, 24: JDN155."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00592-019-01445-z","article-title":"Trend 2010-2018 in the clinical use of GLP-1 receptor agonists for the treatment of type 2 diabetes in routine clinical practice: an observational study from Northeast Italy","volume":"57","author":"25 Fadini","year":"2020","unstructured":"25 Fadini GP, Frison V, Rigato M, et al. Trend 2010-2018 in the clinical use of GLP-1 receptor agonists for the treatment of type 2 diabetes in routine clinical practice: an observational study from Northeast Italy. Acta Diabetol. 2020; 57: 367-375.","journal-title":"Acta Diabetol"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26 Kosiborod M, Aroda VR, Honore JB, et al. Trends in initiation of GLP-1 RA in patients with type 2 diabetes during 2014-2019: a US database study. Eur Heart J 2021; 42(Suppl 1): ehab724.2957.","DOI":"10.1093\/eurheartj\/ehab724.2957"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27 Weiss T, Yang L, Carr RD, et al. Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK. BMJ Open Diabetes Res Care 2022; 10: e002517.","DOI":"10.1136\/bmjdrc-2021-002517"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1161\/CIRCULATIONAHA.120.045888","article-title":"Glucagon-like peptide-1 receptor agonists and heart failure: the need for further evidence generation and practice guidelines optimization","volume":"142","author":"28 Khan","year":"2020","unstructured":"28 Khan SM, Fonarow GC, McGuire DK, et al. Glucagon-like peptide-1 receptor agonists and heart failure: the need for further evidence generation and practice guidelines optimization. Circulation 2020; 142: 1205-1218.","journal-title":"Circulation"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12933-021-01366-8","article-title":"GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs","volume":"20","author":"29 Giugliano","year":"2021","unstructured":"29 Giugliano D, Scappaticcio L, Longo M, et al. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc Diabetol. 2021; 20: 189.","journal-title":"Cardiovasc Diabetol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.3389\/fnins.2019.01112","article-title":"Glucagon-like peptide-1: a focus on neurodegenerative diseases","volume":"13","author":"30 Grieco","year":"2019","unstructured":"30 Grieco M, Giorgi A, Gentile MC, et al. Glucagon-like peptide-1: a focus on neurodegenerative diseases. Front Neurosci 2019; 13: 1112.","journal-title":"Front Neurosci"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"108614","DOI":"10.1016\/j.drugalcdep.2021.108614","article-title":"Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self administration and subjective responses in humans with cocaine use disorder","volume":"221","author":"31 Angarita","year":"2021","unstructured":"31 Angarita GA, Matuskey D, Pittman B, et al. Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self administration and subjective responses in humans with cocaine use disorder. Drug Alcohol Depend. 2021; 221: 108614.","journal-title":"Drug Alcohol Depend"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"819470","DOI":"10.3389\/fphar.2022.819470","article-title":"Possible mechanisms underlying the effects of glucagon-like peptide-1 receptor agonist on cocaine use disorder","volume":"13","author":"32 Zhu","year":"2022","unstructured":"32 Zhu C, Li H, Kong X, et al. Possible mechanisms underlying the effects of glucagon-like peptide-1 receptor agonist on cocaine use disorder. Front Pharmacol. 2022; 13: 819470.","journal-title":"Front Pharmacol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"609110","DOI":"10.3389\/fendo.2021.609110","article-title":"Glucagon-like peptide-1 receptor agonists for non-alcoholic fatty liver disease in type 2 diabetes: a meta-analysis","volume":"12","author":"33 Wong","year":"2021","unstructured":"33 Wong C, Lee MH, Yaow CY, et al. Glucagon-like peptide-1 receptor agonists for non-alcoholic fatty liver disease in type 2 diabetes: a meta-analysis. Front Endocrinol 2021; 12: 609110.","journal-title":"Front Endocrinol"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"34 Mabilleau G, Pereira M, Chenu C. Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists. J Endocrinol. 2018; 236: R29-R42.","DOI":"10.1530\/JOE-17-0278"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3389\/fendo.2017.00098","article-title":"The impact of glucagon-like peptide-1 on bone metabolism and its possible mechanisms","volume":"8","author":"35 Zhao","year":"2017","unstructured":"35 Zhao C, Liang J, Yang Y, et al. The impact of glucagon-like peptide-1 on bone metabolism and its possible mechanisms. Front Endocrinol. 2017; 8: 98.","journal-title":"Front Endocrinol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3390\/medicina58020224","article-title":"The impact of GLP-1 agonists on bone metabolism: a systematic review","volume":"58","author":"36 Daniiloupolou","year":"2022","unstructured":"36 Daniiloupolou I, Vlachou E, Lambrou GI, et al. The impact of GLP-1 agonists on bone metabolism: a systematic review. Medicina 2022; 58: 224.","journal-title":"Medicina"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.3892\/etm.2021.10601","article-title":"Future perspectives in diabesity treatment: semaglutide, a glucagon-like peptide-1 receptor agonist (review)","volume":"22","author":"37 Tilinca","year":"2021","unstructured":"37 Tilinca MC, Tiuca RA, Niculas C, et al. Future perspectives in diabesity treatment: semaglutide, a glucagon-like peptide-1 receptor agonist (review). Exp Ther Med. 2021; 22: 1167.","journal-title":"Exp Ther Med"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/dom.14020","article-title":"Efficacy and safety of once-monthly efpeglenatide in patients with type 2 diabetes: results of a phase 2 placebo-controlled, 16-week randomized dose-finding study","volume":"22","author":"38 Del Prato","year":"2020","unstructured":"38 Del Prato S, Kang J, Trautmann ME, et al. Efficacy and safety of once-monthly efpeglenatide in patients with type 2 diabetes: results of a phase 2 placebo-controlled, 16-week randomized dose-finding study. Diabetes Obes Metab. 2020; 22: 1176-1186.","journal-title":"Diabetes Obes Metab"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"39 Pratley RE, Jacob S, Baek S, et al. Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI and age at baseline. BMJ Open Diabetes Res Care 2022; 10: e002207.","DOI":"10.1136\/bmjdrc-2021-002207"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"29959","DOI":"10.1073\/pnas.2014879117","article-title":"Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist","volume":"117","author":"40 Kawai","year":"2020","unstructured":"40 Kawai T, Sun B, Yoshino H, et al. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. Proc Natl Acad Sci U S A 2020; 117: 29959-29967.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1179551420905844","DOI":"10.1177\/1179551420905844","article-title":"Multiagonist unimolecular peptides for obesity and type 2 diabetes: current advances and future directions","volume":"13","author":"41 Hasib","year":"2020","unstructured":"41 Hasib A. Multiagonist unimolecular peptides for obesity and type 2 diabetes: current advances and future directions. Clin Med Insights Endocrinol Diabetes 2020; 13: 1179551420905844.","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"5580","DOI":"10.1021\/acs.jmedchem.8b00292","article-title":"Dual glucagon-like peptide 1 (GLP-1)\/glucagon receptor agonists specifically optimized for multidose formulations","volume":"61","author":"42 Evers","year":"2018","unstructured":"42 Evers A, Bossart M, Pfeiffer-Marek S, et al. Dual glucagon-like peptide 1 (GLP-1)\/glucagon receptor agonists specifically optimized for multidose formulations. J Med Chem. 2018; 61: 5580-5593.","journal-title":"J Med Chem"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"43 Bajaj HS, Bergenstal RM, Christoffersen A, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in type 2 diabetes inadequately controlled on daily basal insulin: a phase 2 randomized controlled trial. Diabetes Care 2021, 44: 1586-1594.","DOI":"10.2337\/dc20-2877"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/163\/29\/article-p1144.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/163\/29\/article-p1144.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/163\/29\/article-p1144.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T09:02:28Z","timestamp":1698310948000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/163\/29\/article-p1144.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,17]]},"references-count":43,"journal-issue":{"issue":"29"},"URL":"https:\/\/doi.org\/10.1556\/650.2022.32547","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,17]]}}}